Drug Markets/elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

1 NDCs across 1 manufacturers|0 Generic,1 Brand

Total NDCs

0G / 1B

Manufacturers

competing in market

Price Spread

$143.35 – $143.35

7d Activity

1 flat

of 1 total NDCs

Monthly average NADAC price per unit, split by generic and brand

1 manufacturer producing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

1 NDCs total, 1 shown

Drug ↕	NDC	Manufacturer ↕	Price	Market Outlier	Class	7d Change ↕	Therapeutic Class
GENVOYA TABLET	61958190101	Gilead Sciences, Inc.	$143.3501 per EA	—	Brand	—	Cytochrome P450 3A Inhibitor, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor